Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label Phase II Study to Evaluate Safety and Efficacy of Combined Treatment With Ipilimumab and Nivolumab in Patients With Four and More Symptomatic Brain Metastases of Melanoma

NCT03728465 is registered in ClinicalTrials.gov with University Hospital Tuebingen as lead sponsor.

NCT NCT03728465
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03728465 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label Phase II Study to Evaluate Safety and Efficacy of Combined Treatment With Ipilimumab and Nivolumab in Patients With Four and More Symptomatic Brain Metastases of Melanoma
Lead sponsor
University Hospital Tuebingen
Phase
Phase 2
Overall status
Terminated
Start date
April 10, 2018
Completion date
January 1, 2021
Enrollment
6 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

brain metastases, metastatic melanoma